MedTrace Logo

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

NCT00976118 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-12-13

No results posted yet for this study

Summary

This phase 2 study was designed to evaluate the activity of oral masitinib (AB1010) administered at 2 dose levels during 24 weeks to patients with mild to moderate confirmed Alzheimer's type disease.

Conditions

Interventions

DRUG

masitinib (AB1010)

oral masitinib 3 or 6 mg/kg/day

DRUG

placebo

matching placebo to masitinib

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-07-31
Completion
2009-02-28

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00976118 on ClinicalTrials.gov